Anthem Biosciences (ANTHEM) Share Price Falls 2.12% Today as Stock Declines

Published:   28 September 2026 at 2:53:24 PM IST

Anthem Biosciences Share Price fell today, with the stock closing at Rs 855.85 after a decline of Rs 18.50, or 2.12%, from the previous close of Rs 874.35. The company carries a market capitalisation of Rs 49,272.07 Cr, placing it in the Large Cap category. This Anthem Biosciences Share Price move is eventful because the session shows a clear day-level decline even though the supplied data does not establish a company-specific catalyst. For readers tracking Anthem Biosciences Share Price Today, the move is best understood through the day’s price action, the valuation profile and the sector comparison rather than any assumed reason. Univest is using the verified numbers here to separate the confirmed price event from unsupported interpretation.

The stock’s latest move has placed Anthem Biosciences Stock News in focus for market participants searching for Anthem Biosciences Share Price News Today and Anthem Biosciences Share Price Update. Univest’s analysis below focuses on what the numbers actually show, what the company’s valuation says, and what investors may want to monitor next without turning the decline into a narrative that is not supported by the data.

Anthem Biosciences (ANTHEM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 855.85
Previous Close	Rs 874.35
Today's Move	-Rs 18.50 (-2.12%)
Open	Rs 866.75
High	Rs 875.75
Low	Rs 854.1
Turnover	Rs 4.73 crore
Market Capitalisation	Rs 49,272.07 crore
Market Cap Category	Large Cap

Anthem Biosciences Share Price Today moved between Rs 854.10 and Rs 875.75, with the session opening at Rs 866.75. The stock’s current price of Rs 855.85 sits below both the open and the previous close of Rs 874.35, which resulted in a day change of Rs -18.50 and a day change percentage of -2.12%. The session range shows that the stock traded above the low of Rs 854.10 and below the high of Rs 875.75, keeping the day’s movement relatively contained within that band.

Turnover stood at Rs 4.73 Cr for the day, which is a factual value and should be read alongside the price move rather than treated as an explanation for it. For a Large Cap company, the move is meaningful because it changes the near-term price backdrop even without any confirmed event driver. Investors following Anthem Biosciences Share Price Fall can use the current session to compare today’s close with the previous close, the open and the day’s intraday range. That sets up the next question: how does the move sit against the company’s broader market structure and valuation context?

Anthem Biosciences (ANTHEM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 49,272.07 crore
P/E Ratio	85.55x
P/B Ratio	15.74x
ROE	21.98%
ROCE	29.62%
EPS	Rs 10.22
Book Value Per Share	Rs 55.53
Dividend Yield	0.23%

Anthem Biosciences Share Price is trading alongside a market capitalisation of Rs 49,272.07 Cr, a P/E ratio of 85.55 and a P/B ratio of 15.74. Those multiples place Anthem Biosciences Stock Analysis in a premium valuation zone relative to many listed healthcare names, so the price move naturally invites a closer look at earnings power and balance-sheet context. The company’s EPS is Rs 10.22, book value is Rs 55.53 and dividend yield is 0.23%, which together provide the basic per-share earnings, accounting and payout backdrop for Anthem Biosciences Share Price Today.

On profitability ratios, ROE is 21.98% and ROCE is 29.62%, both of which are strong on an absolute basis and useful for investors comparing Anthem Biosciences Fundamental Analysis with other pharmaceuticals and drugs names. The combination of a high valuation with solid return ratios is an important part of the story in Anthem Biosciences Stock News. Univest’s factual reading is that the share price fall has occurred against a backdrop of relatively rich valuation metrics and healthy return ratios, so the session should be interpreted through both price and fundamentals rather than price alone. That leads naturally to sector context and peer comparison.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	85.55x
Benchmark Median P/E	32.87x
Benchmark Average P/E	49.63x
Benchmark P/E Range	3.46x to 735.85x
Company P/B Ratio	15.74x
Benchmark Median P/B	2.85x
Benchmark Average P/B	4.33x
Company ROE	21.98%
Benchmark Median ROE	11.48%
Benchmark Average ROE	10.04%
Company ROCE	29.62%
Benchmark Median ROCE	13.17%
Benchmark Average ROCE	12.82%
Company Market Capitalisation	Rs 49,272.07 crore
Benchmark Median Market Cap	Rs 732.57 crore
Benchmark Average Market Cap	Rs 14,043.26 crore

Anthem Biosciences operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, and the supplied benchmark covers the same industry with 204 companies. Within that scope, Anthem Biosciences Share Price is associated with a company P/E of 85.55 versus a benchmark median of 32.87 and an average of 49.63. The company’s P/B of 15.74 also stands above the benchmark median of 2.85 and average of 4.33. On return ratios, ROE of 21.98% is above the industry median of 11.48%, while ROCE of 29.62% is above the median of 13.17% and the average of 12.82%.

Market-cap context also matters. The benchmark universe shows a median market capitalisation of Rs 732.57 Cr and an average of Rs 14,043.26 Cr, while Anthem Biosciences Share Price corresponds to a market cap of Rs 49,272.07 Cr. That places the company well above the industry median size. In sector analysis, the key takeaway is not a forecast but a comparison: the company’s valuation multiples are above the industry medians, while profitability ratios are also above the benchmark medians. Univest uses such comparisons to help readers understand whether a daily price move is occurring in a rich or modest valuation frame.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,44,716.74	36.77	5.14	14.85	19.11
Divi's Laboratories	DIVISLAB	2,55,115.31	87.22	14.44	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,613.38	86.94	21.13	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,19,899.96	26.57	4.45	19.69	21.39
Cipla	CIPLA	1,12,875.68	33.49	3.21	11.83	16

Among the supplied peers, Anthem Biosciences Share Price sits within a peer set that includes Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla The company’s market capitalisation of Rs 49,272.07 Cr is below Sun Pharmaceutical Industries and Divi's Laboratories, but above Zydus Lifesciences and Cipla The P/E of 85.55 is higher than Sun Pharmaceutical Industries and Zydus Lifesciences, while close to Divi's Laboratories and Torrent Pharmaceuticals in the supplied peer set.

On return ratios, Anthem Biosciences Share Price is paired with ROE of 21.98% and ROCE of 29.62%. That ROCE is above every peer listed here, while ROE is above Sun Pharmaceutical Industries, Divi's Laboratories, Zydus Lifesciences and Cipla, but below Torrent Pharmaceuticals The peer comparison does not establish a cause for the decline; it simply places the stock’s valuation and profitability profile in a broader listed-company frame. For readers of Anthem Biosciences Stock News, this is the most direct way to compare the company without overstating what today’s move means.

Why Investors Are Watching Anthem Biosciences

• Anthem Biosciences Share Price fell 2.12% today to Rs 855.85 from Rs 874.35.
• The day’s range was Rs 854.10 to Rs 875.75, with opening price at Rs 866.75.
• Market capitalisation stands at Rs 49,272.07 Cr, which places the company in the Large Cap category.
• P/E is 85.55, P/B is 15.74, EPS is Rs 10.22 and book value is Rs 55.53.
• ROE is 21.98% and ROCE is 29.62%, both above the industry median in the supplied benchmark.

About Anthem Biosciences

Anthem Biosciences is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company through its listed market profile and valuation metrics rather than through product or segment detail. For this reason, Anthem Biosciences Share Price News Today is best read in the context of its sector classification, earnings-based ratios and benchmark comparison. Univest keeps this section factual and restrained, using only the verified company classification and market data provided in the workflow.

Track Anthem Biosciences Share Price on Univest

Use Anthem Biosciences (ANTHEM) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

Readers can track Anthem Biosciences Share Price on Univest for live market updates, valuation ratios, shareholding pattern views, 52-week levels and broader market insights. The platform also helps users follow Anthem Biosciences Stock Analysis, Anthem Biosciences Fundamental Analysis and Anthem Biosciences Latest News in one place, with verified data presented in a structured format.

Frequently Asked Questions

Why did Anthem Biosciences Share Price fall today?

Ans.  Anthem Biosciences Share Price fell 2.12% to Rs 855.85 today. The supplied data confirms the price decline, but it does not establish a company-specific catalyst behind the move. The previous close was Rs 874.35.

What is Anthem Biosciences Share Price today?

Ans.  Anthem Biosciences Share Price today is Rs 855.85, compared with the previous close of Rs 874.35. The session also saw an open at Rs 866.75 and a low of Rs 854.10.

Is Anthem Biosciences a Large Cap company?

Ans.  Yes. Anthem Biosciences carries a market capitalisation of Rs 49,272.07 Cr and is classified as a Large Cap company in the supplied data. That is a factual size context, not a quality assessment.

How are Anthem Biosciences valuation ratios positioned?

Ans.  Anthem Biosciences has a P/E of 85.55 and a P/B of 15.74. In the supplied industry benchmark, both are above the median and average, which frames the valuation context for the stock.

What do Anthem Biosciences ROE and ROCE show?

Ans.  Anthem Biosciences reports ROE of 21.98% and ROCE of 29.62%. Both are above the benchmark median for the Pharmaceuticals & Drugs industry, indicating strong return ratios in the supplied comparison set.

How does Anthem Biosciences compare with listed peers?

Ans.  Against the supplied peers, Anthem Biosciences has a market cap below Sun Pharmaceutical Industries and Divi's Laboratories, but above Zydus Lifesciences and Cipla Its ROCE is the highest in the set.